EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum SERPINA3 as a Candidate Non-Invasive Biomarker for Neuromyelitis Optica Spectrum Disorder: Proteomic Discovery and Same-Center Validation

Ting Xu, Bingqing Han iD, Guanghui Zheng, Wencan Jiang, Hanyu Zhang, Guojun Zhang

Diagnostics · 20.08.2026 · 16 (16) · 2660

DOI: 10.3390/diagnostics16162660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 20.08.2026. Verfasst von Ting Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Diagnosis, Laboratory of Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Tian Tan Hospital, Beijing Natural Science Foundation, Beijing Tiantan Hospital, Capital Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diagnostic evaluation of suspected neuromyelitis optica spectrum disorder (NMOSD) integrates AQP4-IgG testing, clinical assessment, neuroimaging, and exclusion of alternative inflammatory demyelinating disorders; nevertheless, some patients remain diagnostically unresolved or may be misclassified as multiple sclerosis (MS) or other disorders.

Methods

This single-center retrospective exploratory study analyzed quantitative serum proteomics from 20 patients with MS and 20 with NMOSD. Proteins meeting nominal p < 0.05 together with prespecified fold-change criteria were considered exploratory candidates. VWF, PPBP, and SERPINA3 were subsequently assessed by ELISA in a separate, non-overlapping cohort from the same center, together with routine hematological variables.

Results

Among 261 protein entries, 34 met the exploratory nominal threshold and fold-change criteria, but none remained significant after Benjamini–Hochberg correction (lowest q = 0.0734). VWF and PPBP showed no significant differences across the four validation groups. SERPINA3 differed across groups (Kruskal–Wallis H = 44.982, p = 9.34 × 10−10) and was higher in NMOSD than in MS, TBI, and HCs after Holm adjustment (adjusted p = 0.036, 1.49 × 10−9, and 1.13 × 10−5, respectively). In the full ELISA cohort, the AUC was 0.928 for NMOSD versus HC and 0.800 for NMOSD versus MS. In a post hoc sensitivity analysis excluding participants with preceding infection, the NMOSD–MS separation was attenuated. In smaller complete-case analyses, adding an additional laboratory variable to SERPINA3 did not significantly improve apparent discrimination.

Conclusions

SERPINA3 is therefore an exploratory adjunctive serum biomarker candidate rather than a stand-alone diagnostic test; prospective external validation in clinically representative cohorts is required.

Schlagwörter

Stichwörter der Autor:innen

SERPINA3candidate biomarkerneuromyelitis optica spectrum disorderroutine hematology

Autor:innen und Institutionen

  • Department of Clinical Diagnosis, Laboratory of Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
  • Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University, Beijing 100070, China.
  • Beijing Key Laboratory of Biomarker Screening and Translational Research in Neurological Diseases, Beijing 100070, China.
  • The Fifth Clinical Medical School, Capital Medical University, Beijing 100070, China.

ORCID-Profile: Bingqing Han

Förderung

  • Beijing Tian Tan Hospital
  • Beijing Natural Science Foundation
  • Beijing Tiantan Hospital, Capital Medical University

Zitieren

APA

Xu, T., Han, B., Zheng, G., Jiang, W., Zhang, H., & Zhang, G. (2026). Serum SERPINA3 as a Candidate Non-Invasive Biomarker for Neuromyelitis Optica Spectrum Disorder: Proteomic Discovery and Same-Center Validation. Diagnostics, 16(16), 2660. https://doi.org/10.3390/diagnostics16162660

Vancouver

Xu T, Han B, Zheng G, Jiang W, Zhang H, Zhang G. Serum SERPINA3 as a Candidate Non-Invasive Biomarker for Neuromyelitis Optica Spectrum Disorder: Proteomic Discovery and Same-Center Validation. Diagnostics. 2026;16(16):2660. doi:10.3390/diagnostics16162660

BibTeX
@article{Xu2026,
  author = {Xu, Ting and Han, Bingqing and Zheng, Guanghui and Jiang, Wencan and Zhang, Hanyu and Zhang, Guojun},
  title = {Serum SERPINA3 as a Candidate Non-Invasive Biomarker for Neuromyelitis Optica Spectrum Disorder: Proteomic Discovery and Same-Center Validation},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {16},
  pages = {2660},
  doi = {10.3390/diagnostics16162660}
}
Kostenlos starten →